Xolair Allows Tolerance to Common Food Allergens 

Xolair, the registered name for the drug, omalizumab, was the first drug approved to reduce allergic reactions caused by stray foods. Kids as young as the age of 1 with allergies can take this medication by injection every two to four weeks, depending on their own allergies and on their weight. 

Study Validates Xolair’s Efficacy 

Visual Representation – Xolair or Omalizumab is an Asthma Drug.

Seventeen million people in the U.S. are said to have the types of food allergies that can produce rapid, deep, severe symptoms starting from the whole body, which can be fatal, as reported by The Associated Press. 

Xolair users need to keep avoiding foods like peanuts, cashews, hazelnuts, walnuts, milk products, and eggs that make them react. They can tolerate larger quantities of these items without experiencing severe side effects thanks to the medicine. 

Many allergy sufferers, as well as their families, constantly worry about being exposed to allergens, which makes them avoid social settings like going out to eat. 

“To have this protection is going to be life-changing,” said Dr. Robert Wood, director of the pediatric allergy division at Johns Hopkins Children’s Center. 

The FDA decision is made based on a study executed by Wood and used funding from the National Institutes of Health. It demonstrated that in the case of Xolair, around 68% of the population with peanut allergies was capable of tolerating about 600 milligrams (which means about half a teaspoon) of peanut protein, and just about 6% of those who had dummy injections, as reported by The Associated Press. 

Compared to the other allergens like tree nuts, milk, egg, and wheat, the results were near the same patterns. It is expected that the detailed findings will be presented at a meeting during the upcoming month and subsequently published in a prestigious scientific journal. 

Wood stated that between 25% and 50% of adults and 70% of children and college students would opt for injecting the Xolair. 

Xolair’s Monoclonal Antibody Technology 

Xolair is a monoclonal antibody, and antibodies target a cell with the antigen (the thing that elicits the immune response) recognizing a cell which displays that antigen. Its approval took place in 2003 and essentially, it has proved effective in the treatment of diseases that affect the patients’ breathing, such as asthma, nasal polyps and chronic hives. It originates from drug companies Sanofi and Roche, and is provided by Genentech, a member of the Roche subdivision, as reported by The Associated Press. 

The injection site reactions, along with fever, both fall within the most common side effects of Xolair, but the FDA also reported an association between the drug and joint pain, rash, parasitic infections, malignancies, and the odd laboratory test. The medication, Xolair, is cautioned against the side effects of Angioedema, which can be treated only in a clinical setting, as reported by The Associated Press. 

The drug is not for approved emergency use in an allergic reaction. 

Retail Costs and Accessibility 

The retail cost of Xolair varies between $2,900 per month for children and $5,000 a month for adults. Genentech is the company selling this medication. As a rule, insured patients usually have to pay less overall than when they purchase their supplies at the pharmacy without a cover.